OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Challenges, Sustainability, and Big Trends in Outsourcing Today
Understanding is crucial to ensure the right balance in manufacturing technologies and proccesses is achieved.
Obstacles remain before broader application of intensified processes can be implemented.
Limitations in production platforms have impeded continuous manufacturing for advanced therapies.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
Fundamental Constriction Points in Emerging Therapies
May 19, 2023
Shabbir Mostafa, head of Business Development — Advanced Delivery Systems, Recipharm, sat down with Grant Playter, associate editor, during DCAT week to discuss the current state of inhalations forms and drug delivery.
May 18, 2023
Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.
Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.
ProBioGen’s Lenti.RiGHT is a lentivirus production platform for use in gene transfer applications.
ChargePoint Technology and Famat Sampling’s combination technology is designed to allow for product sampling during the course of production.
Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.
The new partnership hopes to increase funding and awareness of global health security challenges and highlight the role of the pharmaceutical industry in increasing access to medicines and improving health worldwide.
The agency found insanity conditions and CGMP violations at Pharmedica USA, LLC’s Phoenix facility during an inspection.
The UK and Switzerland are negotiating a modern free trade agreement.
UK’s NICE has recommended Kapruvia as a treatment for adult patients with moderate-to-severe chronic kidney disease (CKD)-associated pruritus.